• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊柱关节炎的全球患病率:一项系统评价和Meta回归分析

Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis.

作者信息

Stolwijk Carmen, van Onna Marloes, Boonen Annelies, van Tubergen Astrid

机构信息

Maastricht University Medical Center and School for Public Health and Primary Care, University of Maastricht, Maastricht, The Netherlands.

出版信息

Arthritis Care Res (Hoboken). 2016 Sep;68(9):1320-31. doi: 10.1002/acr.22831. Epub 2016 Jul 27.

DOI:10.1002/acr.22831
PMID:26713432
Abstract

OBJECTIVE

To summarize the prevalence of spondyloarthritis (SpA) and its subtypes in the general population, and to identify demographic and methodologic characteristics that might explain heterogeneity in prevalence estimates.

METHODS

A systematic literature search was performed to identify relevant articles. Risk of bias was assessed and data were extracted. Pooled prevalences were calculated. Potential sources of heterogeneity were explored by subgroup analysis and meta-regression analysis.

RESULTS

The prevalence of SpA ranged from 0.20% (95% confidence interval [95% CI] 0.00-0.66) in South-East Asia to 1.61% (95% CI 1.27-2.00) in Northern Arctic communities; the prevalence of ankylosing spondylitis (AS) from 0.02% (95% CI 0.00-0.21) in Sub-Saharan Africa to 0.35% (95% CI 0.24-0.48) in Northern Arctic communities; and the prevalence of psoriatic arthritis (PsA) from 0.01% (95% CI 0.00-0.17) in the Middle East to 0.19% (95% CI 0.16-0.32) in Europe. The following characteristics were significantly associated with variation in prevalence of SpA, AS, and/or PsA: proportion of females, mean age of the sample, geographic area and setting (demographic characteristics), year of data collection, case finding, and case ascertainment (methodologic characteristics). For the other SpA subgroups, too few studies were available to conduct a meta-analysis, but prevalence estimates of reactive arthritis (range 0.0-0.2%), SpA related to inflammatory bowel disease (range 0.0-0.1%), and undifferentiated SpA (range 0.0-0.7%) were generally low.

CONCLUSION

SpA is a common disease, but with large variation in reported prevalence estimates, which can partly be explained by differences in demographic and methodologic characteristics. Particularly, geographic area as well as case finding account for a substantial part of the heterogeneity.

摘要

目的

总结普通人群中脊柱关节炎(SpA)及其亚型的患病率,并确定可能解释患病率估计异质性的人口统计学和方法学特征。

方法

进行系统的文献检索以识别相关文章。评估偏倚风险并提取数据。计算合并患病率。通过亚组分析和meta回归分析探索异质性的潜在来源。

结果

SpA的患病率在东南亚为0.20%(95%置信区间[95%CI]0.00 - 0.66),在北极北部社区为1.61%(95%CI 1.27 - 2.00);强直性脊柱炎(AS)的患病率在撒哈拉以南非洲为0.02%(95%CI 0.00 - 0.21),在北极北部社区为0.35%(95%CI 0.24 - 0.48);银屑病关节炎(PsA)的患病率在中东为0.01%(95%CI 0.00 - 0.17),在欧洲为0.19%(95%CI 0.16 - 0.32)。以下特征与SpA、AS和/或PsA患病率的变化显著相关:女性比例、样本平均年龄、地理区域和环境(人口统计学特征)、数据收集年份、病例发现和病例确诊(方法学特征)。对于其他SpA亚组,由于可用研究过少无法进行meta分析,但反应性关节炎(范围0.0 - 0.2%)、与炎症性肠病相关的SpA(范围0.0 - 0.1%)和未分化SpA(范围0.0 - 0.7%)的患病率估计通常较低。

结论

SpA是一种常见疾病,但报告的患病率估计差异很大,部分原因可由人口统计学和方法学特征的差异来解释。特别是,地理区域以及病例发现是异质性的重要组成部分。

相似文献

1
Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis.脊柱关节炎的全球患病率:一项系统评价和Meta回归分析
Arthritis Care Res (Hoboken). 2016 Sep;68(9):1320-31. doi: 10.1002/acr.22831. Epub 2016 Jul 27.
2
Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).炎症性关节炎(类风湿性关节炎、强直性脊柱炎、银屑病关节炎、其他脊柱关节炎)疼痛管理的联合治疗
Cochrane Database Syst Rev. 2011 Oct 5(10):CD008886. doi: 10.1002/14651858.CD008886.pub2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
6
The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.炎症性肠病中轴型和外周型脊柱关节炎的患病率和发病率:系统评价和荟萃分析。
J Crohns Colitis. 2017 May 1;11(5):631-642. doi: 10.1093/ecco-jcc/jjw199.
7
Sulfasalazine for ankylosing spondylitis.柳氮磺胺吡啶用于治疗强直性脊柱炎。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD004800. doi: 10.1002/14651858.CD004800.pub2.
8
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
9
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎:系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
10
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.

引用本文的文献

1
Psoriatic arthritis incidence and prevalence trajectory in Poland-public-payer, national-level, long-term data.波兰银屑病关节炎的发病率和患病率变化轨迹——公共支付方、国家级长期数据
Rheumatol Int. 2025 Sep 2;45(9):212. doi: 10.1007/s00296-025-05966-5.
2
A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment.从初始肿瘤坏死因子抑制剂治疗转换后,乌帕替尼、肿瘤坏死因子抑制剂或白细胞介素-17抑制剂在轴性脊柱关节炎患者中的临床疗效的真实世界比较
Rheumatol Ther. 2025 Jul 19. doi: 10.1007/s40744-025-00786-2.
3
Saudi Clinical Practice Guidelines for Management of Axial Spondyloarthritis Disease.
沙特轴性脊柱关节炎疾病管理临床实践指南
Rheumatol Ther. 2025 Jul 8. doi: 10.1007/s40744-025-00779-1.
4
Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms.使用改善病情抗风湿药(DMARD)治疗的慢性炎症性风湿病患者对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的适应性免疫反应
RMD Open. 2025 Jul 5;11(3):e005673. doi: 10.1136/rmdopen-2025-005673.
5
Granulocyte-macrophage colony-stimulating factor may contribute to spondyloarthritis development in HLA-B27 transgenic rat by affecting conventional dendritic cells function.粒细胞巨噬细胞集落刺激因子可能通过影响传统树突状细胞功能,促进HLA - B27转基因大鼠脊柱关节炎的发展。
Arthritis Res Ther. 2025 Jun 13;27(1):124. doi: 10.1186/s13075-025-03586-9.
6
Prevalence and risk factors of renal involvement in seronegative spondyloarthropathies: a systematic review.血清阴性脊柱关节病肾脏受累的患病率及危险因素:一项系统评价
Rheumatol Int. 2025 Jun 7;45(6):151. doi: 10.1007/s00296-025-05907-2.
7
Pharmacovigilance analysis of spondyloarthritis following HPV vaccination based on the VAERS database.基于疫苗不良事件报告系统(VAERS)数据库的人乳头瘤病毒(HPV)疫苗接种后脊柱关节炎的药物警戒分析
Sci Rep. 2025 Jun 6;15(1):20023. doi: 10.1038/s41598-025-05753-z.
8
Demographic and clinical characteristics of spondyloarthritis patients in Jordan: A cross-sectional study.约旦脊柱关节炎患者的人口统计学和临床特征:一项横断面研究。
Clin Rheumatol. 2025 May 16. doi: 10.1007/s10067-025-07487-9.
9
Associations between comorbidities and patient-reported outcomes in axial spondyloarthritis: data from a single-center real-world cohort.中轴型脊柱关节炎共病与患者报告结局之间的关联:来自单中心真实世界队列的数据。
Clin Rheumatol. 2025 May 7. doi: 10.1007/s10067-025-07452-6.
10
Proteomic Profiling of Inflammatory Protein Dysregulation in HLA-B27-Positive Ankylosing Spondylitis: Molecular Signatures and Potential Biomarkers.HLA - B27阳性强直性脊柱炎中炎症蛋白失调的蛋白质组学分析:分子特征与潜在生物标志物
Biomolecules. 2025 Apr 1;15(4):516. doi: 10.3390/biom15040516.